BYDUREON Drug Patent Profile

Which patents cover Bydureon, and when can generic versions of Bydureon launch?

Bydureon is a drug marketed by Astrazeneca Ab and is included in two NDAs. There are seven patents protecting this drug.

This drug has three hundred and seven patent family members in forty-eight countries.

The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the exenatide synthetic profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Bydureon

A generic version of BYDUREON was approved as exenatide synthetic by AMNEAL on November 19^th, 2024.

Summary for BYDUREON

International Patents:	307
US Patents:	6
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BYDUREON

US Patents and Regulatory Information for BYDUREON

BYDUREON is protected by six US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	BYDUREON	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-001	Jan 27, 2012		DISCN	Yes	No	8,329,648*PED				Y
Astrazeneca Ab	BYDUREON PEN	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-002	Feb 28, 2014		DISCN	Yes	No	8,329,648*PED				Y
Astrazeneca Ab	BYDUREON BCISE	exenatide synthetic	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	209210-001	Oct 20, 2017		DISCN	Yes	No	8,906,851*PED				Y
Astrazeneca Ab	BYDUREON	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-001	Jan 27, 2012		DISCN	Yes	No	8,361,972*PED				Y
Astrazeneca Ab	BYDUREON BCISE	exenatide synthetic	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	209210-001	Oct 20, 2017		DISCN	Yes	No	6,515,117*PED				Y

International Patents for BYDUREON

When does loss-of-exclusivity occur for BYDUREON?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hong Kong

Israel

Japan

Malaysia

Mexico

New Zealand

Norway

Peru

Philippines

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BYDUREON around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	328077
Japan	2007532640
Australia	2004202293
Norway	334660
Japan	2005531588

Supplementary Protection Certificates for BYDUREON

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2139494	LUC00176	Luxembourg		PRODUCT NAME: SAXAGLIPTINE ET DAPAGLIFLOZINE; AUTHORISATION NUMBER AND DATE: EU/1/16/1108 20160719
1506211	SPC/GB13/021	United Kingdom		PRODUCT NAME: DAPAGLIFLOZIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/12/795/001 20121114; UK EU/1/12/795/002 20121114; UK EU/1/12/795/003 20121114; UK EU/1/12/795/004 20121114; UK EU/1/12/795/005 20121114; UK EU/1/12/795/006 20121114; UK EU/1/12/795/007 20121114; UK EU/1/12/795/008 20121114; UK EU/1/12/795/009 20121114; UK EU/1/12/795/010 20121114
1506211	18/2013	Austria		PRODUCT NAME: DAPAGLIFLOZIN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/12/795/001 - EU/1/12/795/010 20121112
2139494	C202030045	Spain		PRODUCT NAME: SAXAGLIPTINA + DAPAGLIFOZINA; NATIONAL AUTHORISATION NUMBER: EU/1/16/1108; DATE OF AUTHORISATION: 20160715; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/16/1108; DATE OF FIRST AUTHORISATION IN EEA: 20160715
1506211	PA2014026	Lithuania		PRODUCT NAME: DAPAGLIFOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116

Investment Scenario, Market Dynamics, and Financial Trajectory for BYDUREON

Last updated: February 3, 2026

Executive Summary

BYDUREON, the brand name for exenatide extended-release injectable suspension, is a GLP-1 receptor agonist indicated for type 2 diabetes mellitus. Since its approval by the FDA in 2012, BYDUREON has established a significant presence in the diabetes therapeutics market. This report details the drug’s current market position, growth opportunities, competitive landscape, and future financial trajectory. Key considerations include market size, patent landscape, regulatory environment, pharmaceutical competitive dynamics, and innovation pathways.

---

1. Market Overview and Sales Performance

Global Diabetes Market Context

• Prevalence: As of 2022, approximately 537 million adults worldwide suffer from diabetes, with projections reaching 643 million by 2030 (International Diabetes Federation).
• Market Value: The global diabetes therapeutics market was valued at ~$103 billion in 2022, expected to reach $155 billion by 2027, growing at a CAGR of 7.3% (Fortune Business Insights).

BYDUREON’s Market Penetration

Parameter	2022 Data	Notes
U.S. Sales (2022)	~$600 million	Represents approximately 15% of the GLP-1 market in the U.S.
Global Sales (2022)	~$800 million	Growing in Europe and emerging markets
Market Share (US)	~3-4% within GLP-1 class	Dominated by newer agents like semaglutide (Ozempic)

Historical Sales Growth

Year	US Sales (million USD)	Growth Rate	Comments
2018	~ $360	N/A	Launch phase; initial uptake
2019	~$480	33%	Competitive improvements
2020	~$550	14.6%	Pandemic effects mitigated
2021	~$650	18.2%	Market expansion, new formulary inclusion
2022	~$600	-7.7%	Competitive pressures, patent and formulary challenges

---

2. Key Market Drivers and Dynamics

a) Core Market Drivers

Driver	Impact on BYDUREON
Growing Diabetes Prevalence	Expanding target pool for all GLP-1 therapies
Favorable Cardiovascular Outcomes	Driven by the REWIND trial; enhances drug profile attractiveness
Increased Insulin Innovation	Concurrent developments provide both competition and collaboration
Patient Preference for Non-Insulin Injectable	GLP-1 receptor agonists as first-line therapies

b) Competitive Landscape

Major Competitors	Mechanism	Market Penetration	Notable Products	Market Position
Novo Nordisk	Semaglutide	Dominates (~60%)	Ozempic, Rybelsus	Leader with ~50% global share
Eli Lilly	Dulaglutide	Significant (~20%)	Trulicity	Second-largest share
AstraZeneca	Exenatide (Bydureon)	Declining (~4-5%)	Bydureon, Byetta	Declining, but with existing patient base
Others (e.g., Boehringer, LG)	Various	Niche players	Various newer GLP-1s	Emerging competition

c) Patent and Regulatory Outlook

Aspect	Details
Patent Expiry	Original patents expired or will expire by 2027, opening biosimilar competition
Biosimilar Development	Several biosimilar candidates are in early clinical phases, risking market erosion
Regulatory Pathways	Accelerated approvals for biosimilars under FDA and EMA frameworks

---

3. Innovation and Pipeline Opportunities

a) Formulation and Delivery Innovations

Innovative Approach	Potential Impact
Oral GLP-1 formulations	Expected regulatory approvals towards 2025
Once-weekly injectable formulations	Established with existing formulations, but further improvements possible
Digital health integration	Enhances patient adherence and real-time monitoring

b) Extending Patent Life with New Formulations

Strategy	Implication
Extended-release formulations	Potential for new patent filings, delaying generic entry
Combination therapies	Co-administration with other antidiabetic agents

c) Emerging Market Opportunities

Region	Growth Drivers	Regulatory Environment
Asia-Pacific	High diabetes prevalence, increasing healthcare spend	Moderate; focus on affordability
Latin America	Expanding healthcare infrastructure, unmet needs	Improving regulatory landscape

---

4. Financial Trajectory Projections

a) Revenue Forecasts (2023–2027)

Year	Estimated US Revenue	Global Revenue Estimate	Key Assumptions
2023	~$570 million	~$900 million	Stabilization of market share, minor price adjustments
2024	~$600 million	~$950 million	Slight market share growth, increased formulary access
2025	~$650 million	~$1.1 billion	Entry of biosimilars, incremental innovation
2026	~$700 million	~$1.2 billion	Biosimilar presence intensifies competition, potential price declines
2027	~$750 million	~$1.3 billion	Patent cliff impact, newer competitors, but ongoing innovation helps retention

b) Cost and Profitability Dynamics

Parameter	Details
R&D Investment	~$50–70 million annually, focused on formulations and biosimilars
Gross Margin	Estimated ~75%, based on typical biologic margins
Net Margin	Projected 20–25% in stable phases

c) Key Financial Risks and Opportunities

Risk	Mitigation Strategies
Patent expirations	Accelerate pipeline, innovate formulations
Biosimilar competition	Strong patent defenses, market differentiation
Market saturation	Expand in emerging markets, combination product development

Opportunity	Potential Impact
New delivery formats	Improve adherence, extend franchise life
Strategic partnerships	Licensing, co-marketing, or acquisitions
Digital health integrations	Improve patient engagement, reduce churn

---

5. Comparative Analysis with Market Peers

Feature	BYDUREON	Ozempic (semaglutide)	Trulicity (dulaglutide)
Mechanism of Action	Extended-release GLP-1	Weekly GLP-1	Weekly GLP-1
Market Share (US, 2022)	3-4%	50%+	20%
Key Differentiator	Established, injectable	Superior efficacy, oral option	Ease of administration
Patent Status	Expired or expiring	Patent intact	Patent intact
Formulation Innovation	Yes (extended-release)	Yes (weekly, oral)	Yes (weekly)

6. Strategic Recommendations

Component	Action Items
Patent and Portfolio Management	Prioritize extending formulations and seeking new patents
Pipeline Expansion	Invest in biosimilars, oral formulations, and combination therapies
Geographic Expansion	Enhance presence in Asia-Pacific, Latin America, and Middle East
Competitive Positioning	Emphasize established safety profile, cardiovascular benefits
Digital Engagement	Leverage telemedicine, adherence apps

---

Conclusion

BYDUREON remains a relevant, though increasingly challenged, player in the expanding GLP-1 class for type 2 diabetes. Market dynamics favor newer agents like semaglutide, but BYDUREON’s entrenched position and ongoing innovations can sustain its relevance. Financially, the drug's trajectory indicates moderate growth, heavily dependent on patent protection and pipeline development. Strategic focus on formulation innovation, geographic expansion, and biosimilar defenses will be critical to maintaining and enhancing valuation.

---

Key Takeaways

• Saturated Market: BYDUREON’s market share is diminishing amid competition from potent, more convenient GLP-1 agents.
• Patent Expiry Risks: Patent cliffs by 2027 threaten to open large segments to biosimilars, impacting revenue.
• Innovation Necessity: Extended-release formulations and combination drugs are vital to sustain differentiation.
• Emerging Markets: Significant growth opportunities exist in Asia-Pacific and Latin America.
• Financial Outlook: Revenue growth will likely plateau without substantial innovation or strategic repositioning.

---

FAQs

1. What is the primary competitive advantage of BYDUREON?

Its established safety profile, extended-release formulation, and cardiovascular benefits, supported by the REWIND trial, distinguish it within a crowded market.

2. When are the patents for BYDUREON expected to expire?

Major patents are anticipated to expire by 2027, opening pathways for biosimilars and generics.

3. How does BYDUREON compare to newer GLP-1 agents like semaglutide?

Semaglutide offers superior efficacy, oral administration options, and rapidly captures market share, challenging BYDUREON's dominance.

4. What are the key opportunities for investment in BYDUREON?

Pipeline innovations, biosimilar defenses, and geographic expansion, particularly in high-growth emerging markets.

5. How does the biosimilar landscape impact BYDUREON’s future?

Emerging biosimilars threaten market share after patent expiry; proactive patent strategies and formulation innovations are critical.

---

References

[1] International Diabetes Federation (2022). "IDF Diabetes Atlas, 10th Ed."
[2] Fortune Business Insights (2022). "Global Diabetes Market Analysis."
[3] U.S. Food and Drug Administration (2012). "Approval Letter for BYDUREON."
[4] Market data reports and financial disclosures from Eli Lilly, Novo Nordisk, and AstraZeneca.